| 國立成功大學 |
2023 |
Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, MET-Amplified Non–Small Cell Lung Cancer: TATTON
|
Hartmaier, R.J.;Markovets, A.A.;Ahn, M.J.;Sequist, L.V.;Han, J.-Y.;Cho, B.C.;Yu, H.A.;Kim, S.-W.;Yang, J.C.-H.;Lee, J.-S.;Su, W.-C.;Kowalski, D.M.;Orlov, S.;Ren, S.;Frewer, P.;Ou, X.;Cross, D.A.E.;Kurian, N.;Cantarini, M.;J�nne, P.A. |
| 國立成功大學 |
2023 |
A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-na�ve, cisplatin-ineligible urothelial cancer
|
Galffy, Galffy G.;Lugowska, I.;Poddubskaya, E.V.;Cho, B.C.;Ahn, M.-J.;Han, J.-Y.;Su, W.-C.;Hauke, R.J.;Dyar, S.H.;Lee, D.H.;Serwatowski, P.;Estelles, D.L.;Holden, V.R.;Kim, Y.J.;Vladimirov, Vladimirov V.;Horvath, Z.;Ghose, A.;Goldman, A.;di, Pietro A.;Wang, J.;Murphy, D.A.;Alhadab, Alhadab A.;Laskov, M. |
| 臺大學術典藏 |
2022-09-15T01:09:00Z |
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials
|
Drilon A.; Siena S.; Dziadziuszko R.; Barlesi F.; Krebs M.G.; Shaw A.T.; de Braud F.; Rolfo C.; Ahn M.-J.; Wolf J.; Seto T.; Cho B.C.; Patel M.R.; Chiu C.-H.; John T.; Goto K.; Karapetis C.S.; Arkenau H.-T.; Kim S.-W.; Ohe Y.; Li Y.-C.; Chae Y.K.; Chung C.H.; Otterson G.A.; Murakami H.; Chia-Chi Lin; Tan D.S.W.; Prenen H.; Riehl T.; Chow-Maneval E.; Simmons B.; Cui N.; Johnson A.; Eng S.; Wilson T.R.; Doebele R.C. |
| 臺大學術典藏 |
2022-09-15T01:08:55Z |
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial
|
Paz-Ares L.; Kim T.M.; Vicente D.; Felip E.; Lee D.H.; Lee K.H.; Chia-Chi Lin; Flor M.J.; Di Nicola M.; Alvarez R.M.; Dussault I.; Helwig C.; Ojalvo L.S.; Gulley J.L.; Cho B.C. |
| 臺大學術典藏 |
2022-09-15T01:08:46Z |
Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors
|
Park K.; Tan D.S.W.; Su W.-C.; Cho B.C.; Kim S.-W.; Lee K.H.; Wang C.-C.; Seto T.; Huang D.C.-L.; Jung H.H.; Hsu M.-C.; Bogenrieder T.; Chia-Chi Lin |
| 臺大學術典藏 |
2022-08-19T06:48:41Z |
Three-Year Follow-Up and Response-Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3)
|
Kitagawa Y.; Matsumura Y.; Takazawa A.; Hamamoto Y.; Doki Y.; Yen C.-C.; Kubota Y.; Kim S.-B.; CHIH-HUNG HSU; Holtved E.; Xynos I.; Ahn M.-J.; Kadowaki S.; Cho B.C.; Takahashi M.; Lin C.-Y.; Chin K.; Okada M.; Kato K. |
| 臺大學術典藏 |
2022-08-10T02:37:39Z |
Amivantamab in egfr exon 20 insertion- mutated non-small-cell lung cancer progressing on platinum chemotherapy: Initial results from the chrysalis phase i study
|
Park K.; Haura E.B.; Leighl N.B.; Mitchell P.; Shu C.A.; Girard N.; Viteri S.; Han J.-Y.; Kim S.-W.; Lee C.K.; Sabari J.K.; Spira A.I.; Yang T.-Y.; Kim D.-W.; Lee K.H.; Sanborn R.E.; Trigo J.; Goto K.; Lee J.-S.; CHIH-HSIN YANG; Govindan R.; Bauml J.M.; Garrido P.; Krebs M.G.; Reckamp K.L.; Xie J.; Curtin J.C.; Haddish-Berhane N.; Roshak A.; Millington D.; Lorenzini P.; Thayu M.; Knoblauch R.E.; Cho B.C. |
| 臺大學術典藏 |
2022-06-27T06:59:36Z |
Olmutinib in T790M-positive non–small cell lung cancer after failure of first-line epidermal growth factor receptor-tyrosine kinase inhibitor therapy: A global, phase 2 study
|
Park K.; J?nne P.A.; Kim D.-W.; Han J.-Y.; Wu M.-F.; Lee J.-S.; Kang J.-H.; Lee D.H.; Cho B.C.; CHONG-JEN YU; Pang Y.K.; Felip E.; Kim H.; Baek E.; Noh Y.S. |
| 臺大學術典藏 |
2021-05-02T03:29:22Z |
Olmutinib in T790M-positive non–small cell lung cancer after failure of first-line epidermal growth factor receptor-tyrosine kinase inhibitor therapy: A global, phase 2 study
|
Park K.; J?nne P.A.; Kim D.-W.; Han J.-Y.; Wu M.-F.; Lee J.-S.; Kang J.-H.; Lee D.H.; Cho B.C.; CHONG-JEN YU; Pang Y.K.; Felip E.; Kim H.; Baek E.; Noh Y.S. |
| 臺大學術典藏 |
2021-04-23T05:56:33Z |
Osimertinib in patients with T790M-positive advanced non-small cell lung cancer: Korean subgroup analysis from phase II studies
|
Ahn M.-J.;Han J.-Y.;Kim D.-W.;Cho B.C.;Kang J.-H.;Kim S.-W.;Chih-Hsin Yang;Mitsudomi T.;Lee J.S.; Ahn M.-J.; Han J.-Y.; Kim D.-W.; Cho B.C.; Kang J.-H.; Kim S.-W.; CHIH-HSIN YANG; Mitsudomi T.; Lee J.S. |
| 臺大學術典藏 |
2021-04-23T05:56:31Z |
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study
|
Sequist L.V.;Han J.-Y.;Ahn M.-J.;Cho B.C.;Yu H.;Kim S.-W.;Chih-Hsin Yang;Lee J.S.;Su W.-C.;Kowalski D.;Orlov S.;Cantarini M.;Verheijen R.B.;Mellemgaard A.;Ottesen L.;Frewer P.;Ou X.;Oxnard G.; Sequist L.V.; Han J.-Y.; Ahn M.-J.; Cho B.C.; Yu H.; Kim S.-W.; CHIH-HSIN YANG; Lee J.S.; Su W.-C.; Kowalski D.; Orlov S.; Cantarini M.; Verheijen R.B.; Mellemgaard A.; Ottesen L.; Frewer P.; Ou X.; Oxnard G. |
| 臺大學術典藏 |
2021-04-23T05:56:31Z |
Osimertinib in patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer and leptomeningeal metastases: The BLOOM study
|
Chih-Hsin Yang;Kim S.-W.;Kim D.-W.;Lee J.-S.;Cho B.C.;Ahn J.-S.;Lee D.H.;Kim T.M.;Goldman J.W.;Natale R.B.;Brown A.P.;Collins B.;Chmielecki J.;Vishwanathan K.;Mendoza-Naranjo A.;Ahn M.-J.; CHIH-HSIN YANG; Kim S.-W.; Kim D.-W.; Lee J.-S.; Cho B.C.; Ahn J.-S.; Lee D.H.; Kim T.M.; Goldman J.W.; Natale R.B.; Brown A.P.; Collins B.; Chmielecki J.; Vishwanathan K.; Mendoza-Naranjo A.; Ahn M.-J. |
| 臺大學術典藏 |
2021-04-23T05:56:28Z |
Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations
|
Paik P.K.;Felip E.;Veillon R.;Sakai H.;Cortot A.B.;Garassino M.C.;Mazieres J.;Viteri S.;Senellart H.;Van Meerbeeck J.;Raskin J.;Reinmuth N.;Conte P.;Kowalski D.;Cho B.C.;Patel J.D.;Horn L.;Griesinger F.;Han J.-Y.;Kim Y.-C.;Chang G.-C.;Tsai C.-L.;Chih-Hsin Yang;Chen Y.-M.;Smit E.F.;Van Der Wekken A.J.;Kato T.;Juraeva D.;Stroh C.;Bruns R.;Straub J.;Johne A.;Scheele J.;Heymach J.V.;Le X.; Paik P.K.; Felip E.; Veillon R.; Sakai H.; Cortot A.B.; Garassino M.C.; Mazieres J.; Viteri S.; Senellart H.; van Meerbeeck J.; Raskin J.; Reinmuth N.; Conte P.; Kowalski D.; Cho B.C.; Patel J.D.; Horn L.; Griesinger F.; Han J.-Y.; Kim Y.-C.; Chang G.-C.; Tsai C.-L.; CHIH-HSIN YANG; Chen Y.-M.; Smit E.F.; van der Wekken A.J.; Kato T.; Juraeva D.; Stroh C.; Bruns R.; Straub J.; Johne A.; Scheele J.; Heymach J.V.; Le X. |
| 臺大學術典藏 |
2021-04-23T05:56:27Z |
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial
|
Wu Y.-L.;Cheng Y.;Zhou J.;Lu S.;Zhang Y.;Zhao J.;Kim D.-W.;Soo R.A.;Kim S.-W.;Pan H.;Chen Y.-M.;Chian C.-F.;Liu X.;Tan D.S.W.;Bruns R.;Straub J.;Johne A.;Scheele J.;Park K.;Chih-Hsin Yang;Liu Z.;Chen X.;Wang M.;Yu S.;Zhang H.;Fang J.;Li W.;Yang C.-H.;Chang G.-C.;Hsia T.-C.;Yang C.-T.;Wang C.-C.;Cho B.C.;Lee K.H.;Kim Y.-C.;An H.J.;Woo I.S.;Cho J.Y.;Shin S.W.;Lee J.-S.;Kim J.-H.;Yoo S.S.;Kato T.;Shinagawa N.;Tan S.W.D.;Ngo L.S.-M.;Ratnavelu K.;Ahmad A.R.;Liam C.K.;De Marinis F.;Tassone P.;Molla A.I.;Calles Blanco A.;Lazaro Quintela M.E.;Felip Font E.;Dingemans A.-M.;Bui L.; Wu Y.-L.; Cheng Y.; Zhou J.; Lu S.; Zhang Y.; Zhao J.; Kim D.-W.; Soo R.A.; Kim S.-W.; Pan H.; Chen Y.-M.; Chian C.-F.; Liu X.; Tan D.S.W.; Bruns R.; Straub J.; Johne A.; Scheele J.; Park K.; CHIH-HSIN YANG; Liu Z.; Chen X.; Wang M.; Yu S.; Zhang H.; Fang J.; Li W.; Yang C.-H.; Chang G.-C.; Hsia T.-C.; Yang C.-T.; Wang C.-C.; Cho B.C.; Lee K.H.; Kim Y.-C.; An H.J.; Woo I.S.; Cho J.Y.; Shin S.W.; Lee J.-S.; Kim J.-H.; Yoo S.S.; Kato T.; Shinagawa N.; Tan S.W.D.; Ngo L.S.-M.; Ratnavelu K.; Ahmad A.R.; Liam C.K.; de Marinis F.; Tassone P.; Molla A.I.; Calles Blanco A.; Lazaro Quintela M.E.; Felip Font E.; Dingemans A.-M.; Bui L. |
| 臺大學術典藏 |
2021-01-28T01:06:19Z |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: A JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS
|
Muro K.;Van Cutsem E.;Narita Y.;Pentheroudakis G.;Baba E.;Li J.;Ryu M.-H.;Wan Zamaniah W.I.;Yong W.-P.;Kun-Huei Yeh;Kato K.;Lu Z.;Cho B.C.;Nor I.M.;Ng M.;Chen L.-T.;Nakajima T.E.;Shitara K.;Kawakami H.;Tsushima T.;Yoshino T.;Lordick F.;Martinelli E.;Smyth E.C.;Arnold D.;Minami H.;Tabernero J.;Douillard J.-Y.; Muro K.; Van Cutsem E.; Narita Y.; Pentheroudakis G.; Baba E.; Li J.; Ryu M.-H.; Wan Zamaniah W.I.; Yong W.-P.; KUN-HUEI YEH; Kato K.; Lu Z.; Cho B.C.; Nor I.M.; Ng M.; Chen L.-T.; Nakajima T.E.; Shitara K.; Kawakami H.; Tsushima T.; Yoshino T.; Lordick F.; Martinelli E.; Smyth E.C.; Arnold D.; Minami H.; Tabernero J.; Douillard J.-Y. |
| 臺大學術典藏 |
2021-01-28T01:06:18Z |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: A JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS
|
Muro K.;Lordick F.;Tsushima T.;Pentheroudakis G.;Baba E.;Lu Z.;Cho B.C.;Nor I.M.;Ng M.;Chen L.-T.;Kato K.;Li J.;Ryu M.-H.;Wan Zamaniah W.I.;Yong W.-P.;Kun-Huei Yeh;Nakajima T.E.;Shitara K.;Kawakami H.;Narita Y.;Yoshino T.;Van Cutsem E.;Martinelli E.;Smyth E.C.;Arnold D.;Minami H.;Tabernero J.;Douillard J.-Y.; Muro K.; Lordick F.; Tsushima T.; Pentheroudakis G.; Baba E.; Lu Z.; Cho B.C.; Nor I.M.; Ng M.; Chen L.-T.; Kato K.; Li J.; Ryu M.-H.; Wan Zamaniah W.I.; Yong W.-P.; KUN-HUEI YEH; Nakajima T.E.; Shitara K.; Kawakami H.; Narita Y.; Yoshino T.; Van Cutsem E.; Martinelli E.; Smyth E.C.; Arnold D.; Minami H.; Tabernero J.; Douillard J.-Y. |
| 國立成功大學 |
2021 |
Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors
|
Park, K.;Tan, D.S.W.;Su, W.-C.;Cho, B.C.;Kim, S.-W.;Lee, K.H.;Wang, C.-C.;Seto, T.;Huang, D.C.-L.;Jung, H.H.;Hsu, M.-C.;Bogenrieder, T.;Lin, C.-C. |
| 國立成功大學 |
2021 |
Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC
|
Herbst, R.S.;Garon, E.B.;Kim, D.-W.;Cho, B.C.;Gervais, R.;Perez-Gracia, J.L.;Han, J.-Y.;Majem, Majem M.;Forster, M.D.;Monnet, I.;Novello, S.;Gubens, M.A.;Boyer, M.;Su, W.-C.;Samkari, A.;Jensen, E.H.;Kobie, J.;Piperdi, B.;Baas, P. |
| 臺大學術典藏 |
2020-10-27T12:04:27Z |
Consensus recommendations for management of head and neck cancer in Asian countries: A review of international guidelines
|
Lu T; PEI-JEN LOU; Lin J.C; Kwong D; Hsieh W.S; Hu C; Guo Y; D'Cruz A; Lin T; Anand A.K; Atmakusuma D; Calaguas M.J; Chitapanarux I; Cho B.C; Goh B.C; Prabhash K; Sriuranpong V; Tang P; Vu V.V; Wahid I; Ang K.K; Chan A.T. |
| 臺大學術典藏 |
2020-08-13T06:33:31Z |
Enhancer remodeling and MicroRNA alterations are associated with acquired resistance to ALK inhibitors
|
Yun M.R.; Yun M.R.;Lim S.M.;Kim S.-K.;Choi H.M.;Pyo K.-H.;Kim S.K.;Lee J.M.;Lee Y.W.;Choi J.W.;Kim H.R.;Hong M.H.;Haam K.;Huh N.;Kim J.-H.;Kim Y.S.;Shim H.S.;Soo R.A.;Jin-Yuan Shih;Chih-Hsin Yang J.;Kim M.;Cho B.C.; Cho B.C.; Kim M.; Chih-Hsin Yang J.; JIN-YUAN SHIH; Soo R.A.; Shim H.S.; Kim Y.S.; Kim J.-H.; Lim S.M.; Kim S.-K.; Choi H.M.; Pyo K.-H.; Kim S.K.; Lee J.M.; Lee Y.W.; Choi J.W.; Kim H.R.; Hong M.H.; Haam K.; Huh N. |
| 臺大學術典藏 |
2020-08-13T06:33:31Z |
Enhancer remodeling and MicroRNA alterations are associated with acquired resistance to ALK inhibitors
|
Yun M.R.; Yun M.R.;Lim S.M.;Kim S.-K.;Choi H.M.;Pyo K.-H.;Kim S.K.;Lee J.M.;Lee Y.W.;Choi J.W.;Kim H.R.;Hong M.H.;Haam K.;Huh N.;Kim J.-H.;Kim Y.S.;Shim H.S.;Soo R.A.;Jin-Yuan Shih;Chih-Hsin Yang J.;Kim M.;Cho B.C.; Cho B.C.; Kim M.; Chih-Hsin Yang J.; JIN-YUAN SHIH; Soo R.A.; Shim H.S.; Kim Y.S.; Kim J.-H.; Lim S.M.; Kim S.-K.; Choi H.M.; Pyo K.-H.; Kim S.K.; Lee J.M.; Lee Y.W.; Choi J.W.; Kim H.R.; Hong M.H.; Haam K.; Huh N. |
| 臺大學術典藏 |
2020-05-26T09:27:20Z |
First-line systemic treatment of advanced stage non-small-cell lung cancer in Asia: consensus statement from the Asian Oncology Summit 2009
|
Soo R.A;Anderson B.O;Cho B.C;Chih-Hsin Yang;Liao M;Lim W.-T;Goldstraw P;Mok T.S.; Soo R.A; Anderson B.O; Cho B.C; CHIH-HSIN YANG; Liao M; Lim W.-T; Goldstraw P; Mok T.S. |
| 臺大學術典藏 |
2020-05-26T09:27:20Z |
First-line systemic treatment of advanced stage non-small-cell lung cancer in Asia: consensus statement from the Asian Oncology Summit 2009
|
Soo R.A;Anderson B.O;Cho B.C;Chih-Hsin Yang;Liao M;Lim W.-T;Goldstraw P;Mok T.S.; Soo R.A; Anderson B.O; Cho B.C; CHIH-HSIN YANG; Liao M; Lim W.-T; Goldstraw P; Mok T.S. |
| 臺大學術典藏 |
2020-05-26T09:27:17Z |
The role of monoclonal antibody in combination with first-line chemotherapy in Asian patients with advanced non-small cell lung cancer
|
Cho B.C;Kim J.H;Soo R.A;Chih-Hsin Yang; Cho B.C; Kim J.H; Soo R.A; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:27:17Z |
The role of monoclonal antibody in combination with first-line chemotherapy in Asian patients with advanced non-small cell lung cancer
|
Cho B.C;Kim J.H;Soo R.A;Chih-Hsin Yang; Cho B.C; Kim J.H; Soo R.A; CHIH-HSIN YANG |
